Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 6, 2004, Pages 2199-2205

  Iyer, Radhakrishnan P ^a,d   Jin, Yi ^a,e   Roland, Arlene ^a   Morrey, John D ^b   Mounir, Samir ^a,f   Korba, Brent ^c  

^a Origenix Technologies Inc   (Canada)

^b UTAH STATE UNIVERSITY   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d Spring Bank Technologies Inc   (United States)

^e Biota Inc   (United States)

^f Polygone Pharma Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYCLIC NUCLEOTIDE DERIVATIVE; ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; ORI 7170; ORI 7246; ORI 9020; PHOSPHOROTHIOIC ACID; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; DNA STRAND; DNA STRAND ELONGATION; DRUG MECHANISM; HEPATITIS B VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REBOUND; VIRUS CORE; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS RESISTANCE;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; HEPATITIS B VIRUS; LAMIVUDINE; MUTATION; OLIGODEOXYRIBONUCLEOTIDES; ORGANOTHIOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 2542448256     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.6.2199-2205.2004     Document Type: Article

References (25)

1. Allen, M. I., M. Deslauriers, C. W. Andrews, G. A. Tipples, K. A. Walters, D. L. Tyrrell, N. Brown, L. D. Condreay, et al. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 27:1670-1677.
2. Balfour, H. H., Jr. 1999. Antiviral drugs. N. Engl. J. Med. 340:1255-1268.
3. Belen'kii, M. S., and R. Schinazi. 1994. A method for the analysis of combination therapies with statistical analysis. Antivir. Res. 25:11-18.
4. Bryant, M. L., E. G. Bridges, L. Placidi, A. Faraj, A. G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J. L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, P. Marion, E. Cretton-Scott, R. F. Schinazi, and J. P. Sommadossi. 2001. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45:229-235.
5. Chauret, N., A. Gauthier, J. Martin, and D. A. Nicoll-Griffith. 1997. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat and horse. Drug Metab. Dispos. 25:1130-1136.
6. Ellman, J. A. 1996. Design, synthesis, and evaluation of small-molecule libraries. Acc. Chem. Res. 29:132-143.
7. Jin, Y., A. Roland, W. Zhou, M. Faucbon, J. Lyaku, and R. P. Iyer. 2000. Synthesis and antiviral evaluation of nucleic acid-based (NAB™) libraries. Bioorg. Med. Chem. Lett. 10:1921-1925.
8. Jin, Y., X. Chen, M.-E. Cote, A. Roland, B. Korba, S. Mounir, and R. P. Iyer. 2001. Parallel solid-phase synthesis of nucleoside phosphoramidate libraries. Bioorg. Med. Chem. Lett. 11:2057-2060.
9. Korba, B. E. 1996. In vitro evaluation of combination therapies against hepatitis B virus replication. Antivir. Res. 29:49-51.
10. Korba, B. E., and G. Milman. 1991. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antivir. Res. 15:217-228.
11. Korba, B. E., and J. L. Gerin. 1992. Use of a standardized cell culture assay to determine activities of nucleoside analogs against hepatitis B virus replication. Antivir. Res. 19:55-70.
12. Korba, B. E., and J. L. Gerin. 1995. Antisense oligonucleotides are effective inhibitors of hepatitis B virus replication in vitro. Antivir. Res. 28:225-242.
13. Korba, B. E., P. J. Cote, W. E. Hornbuckle, B. C. Tennant, and J. L. Gerin. 2000. Treatment of chronic woodchuck hepatitis virus infection in the Eastern wood-chuck (Marmota monax) with nucleoside analogues is predictive of therapy for chronic hepatitis B virus infection in humans. Hepatology 31:1165-1175.
14. Lanford, R. E., L. Notvall, and B. Beames. 1995. Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells. J. Virol. 69:4431-4439.
15. Lu, X., A. Mehta, M. Dadmarz, R. Dwek, B. S. Blumberg, and T. M. Block. 1997. Aberrant trafficking of hepatitis B virus glycoproteins in cells in which N-glycan processing is inhibited. Proc. Natl. Acad. Sci. USA 94:2380-2385.
16. Nair, V. 2002. HIV integrase as a target for antiviral chemotherapy. Rev. Med. Virol. 12:179-193.
17. Quan, Y., B. Brenner, G. Oliveira, and M. A. Wainberg. 2003. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob. Agents Chemother. 47:747-754.
18. Roland, A., Y. Xiao, Y. Jin, and R. P. Iyer. 2001. A novel linker for the solid-phase synthesis of a library of 3′-thiophosphorylated dinucleotides. Tetrahedron Lett. 42:3669-3672.
19. Sanger, W. 1984. Protein-nucleic acid interactions, p. 385-431. In W. Sanger (ed.), Principles of nucleic acid structure. Springer-Verlag, New York, N.Y.
20. Schreiber, S. L. 2000. Target-oriented and diversity oriented organic synthesis in drug discovery. Science 287:1964-1969.
21. Sells, M. A., A. Z. Zelent, M. Shvartsman, and G. Acs. 1988. Replication intermediates of hepatitis B virus in HepG2 cells that produce infectious virions. J. Virol. 62:2836-2844.
22. Severini, A., X. Y. Liu, J. S. Wilson, and D. L. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
23. Stuyver, L. J., S. A. Locarnini, A. S. Lok, D. D. Richman, W. F. Carman, J. L. Dienstag, and R. F. Schinazi. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
24. Summers, J., and W. S. Mason. 1982. Replication of the genome of a hepatitis-B-like virus by reverse transcription of an RNA intermediate. Cell 29:403-415.
25. Tatti, K. M., B. E. Korba, H. L. Stang, S. Peek, J. L. Gerin, B. C. Tennant, and R. F. Schinazi. 2002. Mutations in the conserved woodchuck hepatitis virus polymerase FLLA and YMDD regions conferring resistance to lamivudine. Antivir. Res. 55:141-150.